Prolonged vs short duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with or without peripheral arterial disease: A subgroup analysis of the PRODIGY randomized clinical trial

JAMA Cardiology

Volumn 1, Issue 7, 2016, Pages 795-803

  Franzone, Anna ^a   Piccolo, Raffaele ^a   Gargiulo, Giuseppe ^a,b   Ariotti, Sara ^a,c   Marino, Marcello ^a   Santucci, Andrea ^a   Baldo, Andrea ^a   Magnani, Giulia ^a   Moschovitis, Aris ^a   Windecker, Stephan ^a   Valgimigli, Marco ^a,c  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE CORONARY SYNDROME; ADVERSE OUTCOME; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; COMPARATIVE EFFECTIVENESS; DUAL ANTIPLATELET THERAPY; FEMALE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT COURSE THERAPY; STENT THROMBOSIS; TREATMENT DURATION; COMBINATION DRUG THERAPY; COMPLICATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; HYPERPLASIA; INTIMA; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; STENT;

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; PRODIGY; RESIN;

AGED; ASPIRIN; COMPOSITE RESINS; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERPLASIA; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; STENTS; TUNICA INTIMA;

EID: 85009876222     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2016.2811     Document Type: Article

References (31)

1. Berger JS, Petersen JL, Brown DL. Vascular disease burden and in-hospital outcomes among patients undergoing percutaneous coronary intervention in New York State. Circ Cardiovasc Interv. 2009;2(4):317-322.
2. Saw J, Bhatt DL, Moliterno DJ, et al. The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. J Am Coll Cardiol. 2006;48(8): 1567-1572.
3. Poredos P, Jug B. The prevalence of peripheral arterial disease in high risk subjects and coronary or cerebrovascular patients. Angiology. 2007;58(3): 309-315.
4. Agnelli G, Cimminiello C, Meneghetti G, Urbinati S; Polyvascular Atherothrombosis Observational Survey (PATHOS) Investigators. Low ankle-brachial index predicts an adverse 1-year outcome after acute coronary and cerebrovascular events. J Thromb Haemost. 2006;4(12):2599-2606.
5. Kownator S, Cambou JP, Cacoub P, et al. Prevalence of unknown peripheral arterial disease in patients with coronary artery disease: data in primary care from the IPSILON study. Arch Cardiovasc Dis. 2009;102(8-9):625-631.
6. Bhatt DL, Peterson ED, Harrington RA, et al; CRUSADE Investigators. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J. 2009;30(10): 1195-1202.
7. Eagle KA, Rihal CS, Foster ED, Mickel MC, Gersh BJ; The Coronary Artery Surgery Study (CASS) Investigators. Long-term survival in patients with coronary artery disease: importance of peripheral vascular disease. J Am Coll Cardiol. 1994;23(5): 1091-1095.
8. Mukherjee D, Eagle KA, Kline-Rogers E, et al; GRACE Investigators. Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the Global Registry of Acute Coronary Events). Am J Cardiol. 2007;100(1):1-6.
9. Bonaca MP, Creager MA. Pharmacological treatment and current management of peripheral artery disease. Circ Res. 2015;116(9):1579-1598.
10. Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA; CHARISMA Investigators. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009;30(2):192-201.
11. Mauri L, Kereiakes DJ, Yeh RW, et al; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155-2166.
12. Valgimigli M, Costa F, Byrne R, Haude M, Baumbach A, Windecker S. Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey. EuroIntervention. 2015;11(1):68-74.
13. Valgimigli M, Campo G, Monti M, et al; Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012;125(16):2015-2026.
14. Valgimigli M, Campo G, Percoco G, et al. Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention: design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). Am Heart J. 2010;160(5):804-811.
15. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23): 2736-2747.
16. Cutlip DE, Windecker S, Mehran R, et al; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344-2351.
17. Bhatt DL, Eagle KA, Ohman EM, et al; REACH Registry Investigators. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304(12):1350-1357.
18. Vagnarelli F, Corsini A, Lorenzini M, et al. Long-term prognostic role of cerebrovascular disease and peripheral arterial disease across the spectrum of acute coronary syndromes. Atherosclerosis. 2016;245:43-49.
19. Brevetti G, Giugliano G, Brevetti L, Hiatt WR. Inflammation in peripheral artery disease. Circulation. 2010;122(18):1862-1875.
20. McDermott MM, Hoff F, Ferrucci L, et al. Lower extremity ischemia, calf skeletal muscle characteristics, and functional impairment in peripheral arterial disease. J Am Geriatr Soc. 2007; 55(3):400-406.
21. Brilakis ES, Hernandez AF, Dai D, et al. Quality of care for acute coronary syndrome patients with known atherosclerotic disease: results from the Get With the Guidelines Program. Circulation. 2009; 120(7):560-567.
22. Achterberg S, Visseren FL, Kappelle LJ, Pruissen DM, Van Der Graaf Y, Algra A; Smart Study Group. Differential propensity for major hemorrhagic events in patients with different types of arterial disease. J Thromb Haemost. 2011;9(9): 1724-1729.
23. van Hattum ES, Algra A, Lawson JA, Eikelboom BC, Moll FL, Tangelder MJ. Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. Circulation. 2009;120(16):1569-1576.
24. Nikolsky E, Mehran R, Mintz GS, et al. Impact of symptomatic peripheral arterial disease on 1-year mortality in patients undergoing percutaneous coronary interventions. J Endovasc Ther. 2004;11 (1):60-70.
25. Bonaca MP, Bhatt DL, Storey RF, et al. Efficacy and safety of ticagrelor as long-term secondary prevention in patients with peripheral artery disease and prior myocardial infarction. J Am Coll Cardiol. 2016;67(3 suppl):2266.
26. Gremmel T, Xhelili E, Steiner S, Koppensteiner R, Kopp CW, Panzer S. Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: differences between peripheral and coronary angioplasty. Atherosclerosis. 2014;232(1): 119-124.
27. Aradi D, Kirtane A, Bonello L, et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J. 2015;36(27):1762-1771.
28. Tantry US, Bonello L, Aradi D, et al; Working Group on On-Treatment Platelet Reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62(24): 2261-2273.
29. Committee CS; CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329-1339.
30. Bonaca MP, Scirica BM, Creager MA, et al. Vorapaxar in patients with peripheral artery disease: results from TRA2°P-TIMI 50. Circulation. 2013;127(14):1522-1529.
31. clinicaltrials.gov. A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease (EUCLID): NCT01732822. https://clinicaltrials.gov/ct2/show/NCT01732822. Accessed March 8, 2016.